--- title: "Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen" type: "News" locale: "en" url: "https://longbridge.com/en/news/295992685.md" description: "Wall Street Zen downgraded Savara (NASDAQ:SVRA) from a 'hold' to a 'sell' rating. Other analysts maintain mixed views, with an average 'Moderate Buy' rating and a $10.14 price target. Recent institutional activity includes increased stakes by BNP Paribas and Russell Investments. HC Wainwright lowered EPS forecasts due to negative sentiment following quarterly losses. Savara is a clinical-stage biopharmaceutical company developing therapies for rare respiratory diseases." datetime: "2026-08-15T05:54:41.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295992685.md) - [en](https://longbridge.com/en/news/295992685.md) - [zh-HK](https://longbridge.com/zh-HK/news/295992685.md) --- # Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen Savara (NASDAQ:SVRA - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "hold" rating to a "sell" rating in a report issued on Saturday. A number of other research analysts have also recently weighed in on SVRA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Savara in a research report on Friday, July 17th. Oppenheimer assumed coverage on shares of Savara in a report on Friday, April 24th. They issued an "outperform" rating and a $11.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $10.14. **Get Our Latest Research Report on SVRA** ## Savara Price Performance NASDAQ SVRA opened at $5.38 on Friday. The company has a market capitalization of $1.11 billion, a PE ratio of -9.28 and a beta of 0.29. The company has a debt-to-equity ratio of 0.21, a quick ratio of 13.47 and a current ratio of 10.13. The business's fifty day moving average is $5.65 and its 200 day moving average is $5.48. Savara has a fifty-two week low of $2.92 and a fifty-two week high of $7.01. Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Sell-side analysts predict that Savara will post -0.62 earnings per share for the current year. ## Institutional Investors Weigh In On Savara Large investors have recently made changes to their positions in the company. Prudential Financial Inc. purchased a new stake in shares of Savara in the second quarter worth about $30,000. BNP Paribas Financial Markets boosted its position in shares of Savara by 52.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 13,473 shares of the company's stock valued at $31,000 after acquiring an additional 4,626 shares during the last quarter. Brevan Howard Capital Management LP bought a new position in shares of Savara during the 2nd quarter valued at approximately $33,000. Russell Investments Group Ltd. boosted its position in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company's stock valued at $37,000 after acquiring an additional 9,463 shares during the last quarter. Finally, CIBC Bancorp USA Inc. purchased a new position in shares of Savara in the third quarter valued at $44,000. 87.93% of the stock is owned by institutional investors. ## Trending Headlines about Savara Here are the key news stories impacting Savara this week: - Negative Sentiment: HC Wainwright lowered its 2026 EPS forecast to a loss of **$0.62** from a loss of $0.59, below the current consensus estimate of a $0.57 loss. Quarterly estimates were also reduced to losses of $0.16 for the third quarter and $0.15 for the fourth quarter. - Negative Sentiment: The firm cut its 2027 EPS forecast to a loss of **$0.37** from $0.34 and its 2028 forecast to a loss of $0.06 from $0.04, indicating continued operating losses over the next several years. - Negative Sentiment: Longer-term estimates were also reduced: 2029 EPS was lowered to $0.09 from $0.11, while 2030 EPS was cut to $0.37 from $0.39. Although these forecasts still point to eventual profitability, the reductions weaken the near- and long-term earnings outlook. - Neutral Sentiment: The revisions follow Savara’s recent quarterly results, in which the company reported a $0.16-per-share loss versus the $0.14 loss analysts expected. Investors may therefore remain focused on cash usage, execution and progress toward commercialization. ## Savara Company Profile (Get Free Report) Savara Inc NASDAQ: SVRA is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need. The company's lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant. ## Read More - Five stocks we like better than Savara - Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors - Quantum Leaps: Debt-Free as AI Storage Demand Accelerates - NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270 - Sandisk’s Margins Look Like Software. Can They Last? _This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com._ Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Savara Right Now? Before you consider Savara, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Savara wasn't on the list. While Savara currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [SVRA.US](https://longbridge.com/en/quote/SVRA.US.md) - [BNPQY.US](https://longbridge.com/en/quote/BNPQY.US.md) - [PRU.US](https://longbridge.com/en/quote/PRU.US.md) - [CM.US](https://longbridge.com/en/quote/CM.US.md) - [SONY.US](https://longbridge.com/en/quote/SONY.US.md) - [6758.JP](https://longbridge.com/en/quote/6758.JP.md) - [TSM.US](https://longbridge.com/en/quote/TSM.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [SNDK.US](https://longbridge.com/en/quote/SNDK.US.md) - [PRS.US](https://longbridge.com/en/quote/PRS.US.md) - [PFH.US](https://longbridge.com/en/quote/PFH.US.md) - [PRH.US](https://longbridge.com/en/quote/PRH.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [SVRA: MOLBREEVI shows strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market](https://longbridge.com/en/news/295577539.md) - [MediWound (NASDAQ:MDWD) Issues Earnings Results](https://longbridge.com/en/news/295866831.md) - [25 rare and beautiful coins that are worth millions](https://longbridge.com/en/news/295960689.md) - [Are bicentennial quarters more valuable as America approaches 250th anniversary?](https://longbridge.com/en/news/296026473.md) - [Savara Q2 loss widens as operating expenses rise](https://longbridge.com/en/news/295574578.md)